https://www.yiliao.com/index.php?action=history&feed=atom&title=GB241
GB241 - 版本历史
2026-04-18T15:50:33Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=GB241&diff=314633&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T04:57:27Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[GB241]]</strong>是一种由<strong>[[嘉和生物]]</strong>（[[Genor Biopharma]]）开发的重组人鼠嵌合型抗<strong>[[CD20]]</strong>单克隆抗体。作为<strong>[[利妥昔单抗]]</strong>（[[Rituximab]]，商品名：[[美罗华]]/[[Rituxan]]）的生物类似药，[[GB241]]特异性结合B淋巴细胞表面的<strong>[[CD20]]</strong>抗原。该药物通过诱导[[抗体依赖性细胞介导的细胞毒作用]]（[[ADCC]]）、[[补体依赖的细胞毒作用]]（[[CDC]]）以及直接诱导[[细胞凋亡]]，精准清除恶性B细胞。[[GB221]]主要用于治疗<strong>[[非霍奇金淋巴瘤]]</strong>（[[NHL]]）、[[慢性淋巴细胞白血病]]（[[CLL]]）以及多种[[自身免疫性疾病]]，是血液肿瘤免疫治疗的基石药物之一。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[GB241]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[利妥昔单抗]]生物类似药 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[GB241]]抗体分子结构模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[MS4A1]] ([[CD20]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">931([[MS4A1]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7315</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[人鼠嵌合单克隆抗体]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 145 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[静脉滴注]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研发厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[嘉和生物]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多重免疫联合打击</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB241]]通过与B细胞表面的[[CD20]]抗原跨膜结构结合，启动一系列效应机理清除病理性B细胞：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>ADCC效应：</strong>抗体的[[Fc段]]结合效应细胞（如[[NK细胞]]、[[巨噬细胞]]）表面的[[Fcγ受体]]，介导效应细胞释放[[穿孔素]]和[[颗粒酶]]裂解靶细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>CDC效应：</strong>抗体与[[CD20]]结合后激活补体经典通路，形成[[膜攻击复合物]]（[[MAC]]），导致靶细胞发生[[渗透性溶解]]。</li><br />
<li style="margin-bottom: 12px;"><strong>诱导细胞凋亡：</strong>抗体与[[CD20]]分子的跨膜结合可干扰胞内信号传导，直接启动[[Caspase]]依赖性的程序性细胞死亡。</li><br />
<li style="margin-bottom: 12px;"><strong>化疗增敏：</strong>[[GB241]]能够通过改变细胞生存信号通路，增强肿瘤细胞对传统化疗药物（如[[环磷酰胺]]、[[多柔比星]]）的敏感性。</li><br />
</ul><br />
<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：GB241 治疗矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">推荐方案</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值表现</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[DLBCL]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">R-CHOP方案</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">显著提升弥漫大B细胞淋巴瘤的治愈率和五年生存率。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[滤泡性淋巴瘤]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">单药维持或联合化疗</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">有效延长[[PFS]]，减少疾病复发。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[类风湿关节炎]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">二线及以后治疗</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对抗[[TNF]]治疗效果不佳的患者，提供深度的B细胞耗竭。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：安全滴注与全过程管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB241]]的临床使用需关注输注反应及长效免疫监测：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>输注前预处理：</strong>建议在首次输注前给予[[糖皮质激素]]、[[解热镇痛药]]及[[抗组胺药]]，以预防常见的[[输注相关反应]]（[[IRR]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>乙肝病毒激活风险：</strong>治疗前必须筛查[[HBsAg]]及[[HBcAb]]。对既往感染者需进行[[预防性抗病毒治疗]]，以防止致命性的[[乙肝病毒再激活]]。</li><br />
<li style="margin-bottom: 12px;"><strong>免疫球蛋白水平监测：</strong>由于长期耗竭B细胞，部分患者可能出现[[低丙种球蛋白血症]]，需定期监测[[IgG]]水平并关注肺部感染风险。</li><br />
<li style="margin-bottom: 12px;"><strong>肿瘤溶解综合征：</strong>针对高肿瘤负荷患者，需注意[[肿瘤溶解综合征]]（[[TLS]]）的监测，并进行充分水化。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CD20]]：</strong>成熟B细胞及恶性B细胞表面的关键标志物，[[GB241]]的唯一打击靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[美罗华]] (Rituxan)：</strong>[[GB241]]对标的利妥昔单抗原研药。</li><br />
<li style="margin-bottom: 8px;"><strong>[[R-CHOP]]：</strong>非霍奇金淋巴瘤的一线化疗金标准方案。</li><br />
<li style="margin-bottom: 8px;"><strong>[[B细胞耗竭]]：</strong>通过抗体清除体内的B淋巴细胞，以达到抗肿瘤或抗自身免疫的效果。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Genor Biopharma clinical archive.</strong> <em>Pharmacokinetic and efficacy equivalence study of GB241 and Rituximab in B-cell NHL.</em> <strong>[[Chinese Journal of Cancer Research]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究证实了GB241与利妥昔单抗在药代动力学及临床终点上具有高度等效性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Coiffier B, et al. (2002).</strong> <em>CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：该研究奠定了利妥昔单抗类药物在NHL治疗中的绝对核心地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[GB241]] ([[利妥昔单抗]]类似药) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CD20]]•[[FcγR]]•[[C1q]]•[[IgG1]]•[[B-cell]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞品/同类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[美罗华]]•[[汉利康]]•[[奥妥珠单抗]] (Gazyva)•[[奥法木单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[嘉和生物]]•[[罗氏]]•[[NMPA]]•[[FDA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[抗CD20单抗联合双特异性抗体]]•[[皮下注射剂型的开发]]•[[针对CAR-T治疗后的维持方案]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164